Document is current

Documents that mention this clinical trial

396 Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side
https://doi.org/10.1136/jitc-2020-sitc2020.0396

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
https://doi.org/10.1200/jco.2023.41.16_suppl.6038

410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers
https://doi.org/10.1136/jitc-2020-sitc2020.0410

682 Changing the radiation and immune-oncology paradigm with the radioenhancer NBTXR3: overcoming resistance to anti-PD-1 blockade from the bench to the clinic
https://doi.org/10.1136/jitc-2022-sitc2022.0682

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.
https://doi.org/10.1200/jco.2024.42.16_suppl.6035

684 NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)
https://doi.org/10.1136/jitc-2022-sitc2022.0684